Celgene Corporation (CELG) : Boston Advisors reduced its stake in Celgene Corporation by 2.48% during the most recent quarter end. The investment management company now holds a total of 320,977 shares of Celgene Corporation which is valued at $34,700,823 after selling 8,170 shares in Celgene Corporation , the firm said in a disclosure report filed with the SEC on Jul 26, 2016.Celgene Corporation makes up approximately 0.84% of Boston Advisors’s portfolio.
Other Hedge Funds, Including , Hl Financial Services boosted its stake in CELG in the latest quarter, The investment management firm added 50 additional shares and now holds a total of 3,068 shares of Celgene Corporation which is valued at $331,681. Celgene Corporation makes up approx 0.01% of Hl Financial Services’s portfolio.Financial Architects Inc boosted its stake in CELG in the latest quarter, The investment management firm added 200 additional shares and now holds a total of 1,767 shares of Celgene Corporation which is valued at $191,030. Celgene Corporation makes up approx 0.05% of Financial Architects Inc’s portfolio.Shinko Asset Management Ltd. reduced its stake in CELG by selling 56 shares or 2.72% in the most recent quarter. The Hedge Fund company now holds 2,000 shares of CELG which is valued at $215,040.Morgens Waterfall Vintiadis Co Inc boosted its stake in CELG in the latest quarter, The investment management firm added 30,000 additional shares and now holds a total of 56,000 shares of Celgene Corporation which is valued at $6,021,120. Celgene Corporation makes up approx 5.89% of Morgens Waterfall Vintiadis Co Inc’s portfolio.Balasa Dinverno Foltz reduced its stake in CELG by selling 220 shares or 5.31% in the most recent quarter. The Hedge Fund company now holds 3,924 shares of CELG which is valued at $402,995. Celgene Corporation makes up approx 0.07% of Balasa Dinverno Foltz’s portfolio.
Celgene Corporation opened for trading at $110.66 and hit $112.43 on the upside on Friday, eventually ending the session at $112.19, with a gain of 0.84% or 0.93 points. The heightened volatility saw the trading volume jump to 54,86,248 shares. Company has a market cap of $86,903 M.
On the company’s financial health, Celgene Corporation reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.39. The company had revenue of $2754.00 million for the quarter, compared to analysts expectations of $2709.02 million. The company’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS.
Many Wall Street Analysts have commented on Celgene Corporation. Stifel Initiated Celgene Corporation on Jul 15, 2016 to “Buy”, Price Target of the shares are set at $138.Company shares were Reiterated by Sun Trust Rbsn Humphrey on Apr 29, 2016 to “Buy”, Firm has raised the Price Target to $ 147 from a previous price target of $145 .
Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.